The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
The innovative eyedrop targets inflammation and pain following ocular surgery
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
The NDA filing is supported by results from the phase III evERA Breast Cancer study
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
Subscribe To Our Newsletter & Stay Updated
